CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2013-03-18): EU expands use of Pegasys to kids with chronic hepatitis C


EU expands use of Pegasys to kids with chronic hepatitis C

Last Updated: 2013-03-18 11:00:12 -0400 (Reuters Health)

ZURICH (Reuters) - Roche said on Monday the European Medicines Agency (EMA) has expanded the approval of its pegylated interferon alfa-2a (Pegasys) plus ribavirin for the treatment of chronic hepatitis C virus (HCV) to children five years of age and older.

The new label for the medicine that was first approved in the European Union over 10 years ago includes children five years and older who have not received treatment and have tested positive for HCV, Roche said in a statement.

Pegasys, in combination with the antiviral ribavirin, is the foundation of treatment for chronic HCV in adults, Roche said.

Mother-to-child transmission of HCV is the most common route of acquiring the infection in children with approximately 65,000 children estimated to live with chronic HCV in Europe, Roche said.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.